AU2003250221A1 - Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 6(cxcr6) - Google Patents

Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 6(cxcr6)

Info

Publication number
AU2003250221A1
AU2003250221A1 AU2003250221A AU2003250221A AU2003250221A1 AU 2003250221 A1 AU2003250221 A1 AU 2003250221A1 AU 2003250221 A AU2003250221 A AU 2003250221A AU 2003250221 A AU2003250221 A AU 2003250221A AU 2003250221 A1 AU2003250221 A1 AU 2003250221A1
Authority
AU
Australia
Prior art keywords
cxcr6
therapeutics
diagnostics
diseases associated
chemokine receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003250221A
Inventor
Ulf Bruggemeier
Stefan Golz
Holger Summer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of AU2003250221A1 publication Critical patent/AU2003250221A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406Neurotransmitters
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003250221A 2002-08-19 2003-08-07 Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 6(cxcr6) Abandoned AU2003250221A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02018155 2002-08-19
EP02018155.8 2002-08-19
PCT/EP2003/008764 WO2004019046A1 (en) 2002-08-19 2003-08-07 Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 6(cxcr6)

Publications (1)

Publication Number Publication Date
AU2003250221A1 true AU2003250221A1 (en) 2004-03-11

Family

ID=31896830

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003250221A Abandoned AU2003250221A1 (en) 2002-08-19 2003-08-07 Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 6(cxcr6)

Country Status (2)

Country Link
AU (1) AU2003250221A1 (en)
WO (1) WO2004019046A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120064089A1 (en) * 2002-11-15 2012-03-15 Morehouse School Of Medicine Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration
WO2008146272A2 (en) * 2007-05-31 2008-12-04 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for treating cxcr6/cxcl16 associated diseases
EP2164508B1 (en) 2007-06-04 2014-01-08 Rappaport Family Institute for Research in the Medical Sciences Agents for the treatment of inflammatory diseases and methods of using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824504A (en) * 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
GB9806677D0 (en) * 1998-03-27 1998-05-27 Smithkline Beecham Plc Novel compounds
ES2339326T3 (en) * 1999-10-12 2010-05-19 Chemocentryx, Inc. CHEMIOQUINE RECEIVER.
US6319675B1 (en) * 1999-11-24 2001-11-20 Millennium Pharmaceuticals, Inc. Methods for detecting and/or identifying agents which bind and/or modulate function of “bonzo” chemokine receptor
AU2001250412A1 (en) * 2000-03-31 2001-10-08 Ipf Pharmaceuticals Gmbh Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides

Also Published As

Publication number Publication date
WO2004019046A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
AU2003251471A1 (en) Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5)
AU2003301894A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
AU2003250221A1 (en) Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 6(cxcr6)
AU2003229767A1 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
AU2003276136A1 (en) Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
AU2003229753A1 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
AU2003273994A1 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
AU2003240589A1 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 4 (gpr4)
AU2003205627A1 (en) Diagnostics and therapeutics for diseases associated with gpr72
AU2003250128A1 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 37 (gpr37)
AU2003233333A1 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 10 (ccr10)
AU2003232750A1 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 11 (ccr11)
AU2003267443A1 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
AU2003279361A1 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7B (PDE7b)
AU2003283427A1 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 9a1 (pde9a1)
AU2003294728A1 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 9a2 (PDE9a2)
AU2003229736A1 (en) Diagnostics and therapeutics for diseases associated with neurotensin receptor 1 (nt1)
AU2003206749A1 (en) Diagnostics and therapeutics for diseases associated with the gpr65 receptor
AU2003289894A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 9a4 (pde9a4)
AU2003216866A1 (en) Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)
AU2003288171A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 9a3 (pde9a3)
AU2003274083A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 10a (pde10a)
AU2003301892A1 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)
AU2003276097A1 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 42 (gpr42)
AU2003283266A1 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 14 (gpr14)

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase